Representative before the EPO

Employment test 1 - 10 employees
Company dna avidity ip ltd
no operation time available
Headquarter in Cambridge and 2 offices
active in Legal Services

Representative before the EPO

Employment test 51 - 200 employees
Company dna mathys and squire llp
no operation time available
Headquarter in London and 5 offices
active in Legal Services and Matchmaking and Trading

James Roger Wilding has worked on the following 22 EPO patent applications which have been published in the last five years:

EP11840988

IMMUNOGENIC COMPOSITIONS

IPC classification:
A61K 9/107, A61K 39/118, A61P 31/04, A61P 37/04
Applicant:
Sanofi Pasteur SA
Agent:
Multiple attorneys, Avidity IP Ltd
Status:
GRANT OF PATENT INTENDED
EP11799550

COMPOSITION FOR IMMUNIZATION AGAINST STREPTOCOCCUS PNEUMONIAE

IPC classification:
A61K 39/09
Applicant:
Sanofi Pasteur Limited
Agent:
Multiple attorneys, Avidity IP Ltd
Status:
EXAMINATION IN PROGRESS
EP12175773

Therapeutic use of anti-tweak receptor antibodies

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
AbbVie Biotherapeutics Inc.
Agent:
James Roger Wilding, Avidity IP Ltd
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12195331

Nicking and extension amplification reaction for the exponential amplification of nucleic acids

IPC classification:
C12Q 1/68
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Patent Boutique LLP
Status:
EXAMINATION REQUESTED
EP12195333

Nicking and extension amplification reaction for the exponential amplification of nucleic acids

IPC classification:
C12Q 1/68
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Patent Boutique LLP
Status:
EXAMINATION IN PROGRESS
EP12767452

MONITORING RECOMBINASE POLYMERASE AMPLIFICATION MIXTURES

IPC classification:
C12P 19/34, C12Q 1/68
Applicant:
Alere San Diego Inc
Agent:
Multiple attorneys, Avidity IP Ltd
Agent:
Jon Philip Broughton, Patent Boutique LLP
Agent:
Jon Philip Broughton, Broughton IP
Status:
EXAMINATION IN PROGRESS
EP14717952

TOXOID, COMPOSITIONS AND RELATED METHODS

IPC classification:
A61K 39/02, C07K 14/33
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP14722469

TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61K 35/14, A61P 35/00, C07K 14/705, C07K 14/725, C07K 16/28, C07K 16/30, C12N 5/0783
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION IN PROGRESS
EP14737429

COMPOSITIONS AND METHODS OF IMMUNIZING AGAINST C. DIFFICILE

IPC classification:
A61K 39/00, A61K 39/08
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
GRANT OF PATENT INTENDED
EP13168383

Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib

IPC classification:
A61K 31/454, A61K 31/573, A61K 31/69, A61K 39/395, A61K 45/06, A61P 35/00
Applicant:
Dana-Farber Cancer Institute, Inc.
Applicant:
AbbVie Biotherapeutics Inc.
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Sarah Elizabeth Roques, J A Kemp
Status:
PATENT GRANTED
EP13168364

Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies

IPC classification:
A61K 31/454, A61K 31/69, A61K 38/55, A61K 39/395, A61K 45/06, A61P 35/00
Applicant:
Dana-Farber Cancer Institute, Inc.
Applicant:
AbbVie Biotherapeutics Inc.
Agent:
James Roger Wilding, Avidity IP Ltd
Agent:
Sarah Elizabeth Roques, J A Kemp
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14871351

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

IPC classification:
A61K 48/00, A61P 35/00, C07K 14/725, C07K 16/46, C12N 15/13, C12N 15/62, C12N 15/63
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania - Center for Technology Transfer
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP14872734

REGULATABLE CHIMERIC ANTIGEN RECEPTOR

IPC classification:
C07K 19/00, C12N 5/0783
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania - Center for Technology Transfer
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15704414

ENHANCED ANTIGEN PRESENTING ABILITY OF CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES

IPC classification:
C07K 14/705, C07K 14/725, C12N 5/0783
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15764851

REGULATABLE CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61K 38/00, A61K 39/00
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15719043

TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61K 31/00, A61K 35/17, A61P 35/02, C12N 5/0783
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15745069

TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61K 31/436, A61K 35/17, A61K 39/395, A61P 35/02, C07K 14/705, C07K 14/725, C07K 16/28, C07K 16/30
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania - Center for Technology Transfer
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15744448

TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR

IPC classification:
A61K 35/17, C07K 14/725, C07K 16/28
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15756525

ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) FOR USE IN CANCER TREATMENT

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
EXAMINATION REQUESTED
EP15745335

SORTASE MOLECULES AND USES THEREOF

IPC classification:
C12N 9/64
Applicant:
Novartis AG
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP15753232

COMBINATIONS OF LOW, IMMUNE ENHANCING. DOSES OF MTOR INHIBITORS AND CARS

IPC classification:
A61K 31/4745, A61K 39/00
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made
EP15774791

TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY

IPC classification:
C07K 14/705, C07K 14/735, C07K 16/28, C07K 16/30
Applicant:
Novartis AG
Applicant:
The Trustees of The University of Pennsylvania
Agent:
James Roger Wilding, Mathys & Squire LLP
Status:
Request for examination was made

Please Sign in to use this feature